Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche/GSK Boniva price

Executive Summary

The wholesale acquisition cost of Roche/GlaxoSmithKline's once-monthly osteoporosis agent Boniva (ibandronate) is $64.28 per tablet, comparable to the monthly cost of Merck's once-weekly Fosamax. Roche/GSK plan to launch Boniva by the end of April (1"The Pink Sheet" April 4, 2005, p. 4)...

You may also be interested in...



Roche/GSK Boniva Launch Plan Includes Reminders For Once-Monthly Dose

Roche and GlaxoSmithKline will support the launch of the osteoporosis therapy Boniva (ibandronate) with a program intended to help patients comply with the once-monthly oral dosing regimen

AACR Round-Up: BMS, Lilly, iTeos, Affimed, Treovir, Revolution And Cardiff

iTeos presents early anti-TIGIT results, Affimed reports 100% response rate in Hodgkin lymphoma, Treovir will start a pivotal Phase II after Phase I pediatric glioma study, updates in KRAS-mutated cancers from Revolution Medicines and Cardiff Oncology, plus Opdivo plus chemo shows complete responses in neoadjuvant lung cancer and Lilly’s Retevmo is active in additional tumors.

India Remdesivir Saga: Exports Barred, Ramp Up Plans And Panic

India stops remdesivir exports amid steep surge in COVID-19 cases, while licensees of Gilead’s antiviral progress multiple measures to ramp up production to meet local demand. One badly affected state stresses the need to stem panic given the limitations of the treatment, even as some non-licensees of the drug apparently seek to contribute to supplies.

Topics

UsernamePublicRestriction

Register

PS045685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel